Category

News
Chimeric antigen receptor (CAR) T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma (DLBCL), with research now exploring ways to shift these agents earlier in the treatment paradigm, according to a discussion at the 2nd Annual Live Medical Crossfire on Hematologic Malignancies. The quick arrival of...
Continue Reading
Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD. These recent data have not only suggested that patients with MCL can expect a better quality of life with novel therapies, but also...
Continue Reading
Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them. The team described its methodology (“Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach”) in JCO Precision...
Continue Reading
Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments, according to results from a network meta-analysis. “The continuous therapy approach has been evaluated extensively in patients with newly diagnosed multiple myeloma, across age groups and treatment strategies upfront, in several trials with different designs,” Francesca Gay, MD,...
Continue Reading
A high level of resilience—or a person’s ability to adapt to adversity—was associated with a better mental and physical health-related quality of life (HRQOL) among patients with multiple myeloma and its precursor diseases, according to the results of a study published in BMJ Open. Early stages of multiple myeloma are usually asymptomatic, but survivors of myeloma often deal...
Continue Reading
Survival outcomes in “real world” practice may differ among nontransplant patients with multiple myeloma who receive routine care compared with clinical trials, according to a study published in the Annals of Hematology. Although the treatment of multiple myeloma has advanced in recent years, new treatment modalities have largely been evaluated in prospective clinical studies with strict inclusion criteria...
Continue Reading
New investigational therapies in the pipeline that address multiple myelomainclude both small-molecule and immunotherapeutic approaches — and in some cases, a combination of the two. Drugs that increase the visibility of tumors to the immune system, used in combination with additional medications that bolster the immune system, will be the future focus in the management of...
Continue Reading
When patients with multiple myeloma become refractory to lenalidomide (Revlimid) or bortezomib (Velcade), or have penta-refractory disease, there have been limited options left for treatment, according to Suman Kambhampati, MD. Recent studies presented at the 2018 ASCO Annual Meeting indicate that meaningful changes may be on the horizon. Notably, the anti-BCMA CAR T-cell therapy bb2121...
Continue Reading
Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell lymphoma and B-cell acute lymphoblastic leukemia — and is currently being investigated for more cancer types. CAR T-cell therapy comprises T cells collected from a patient that are then engineered to recognize an...
Continue Reading
INVITATION Patient Seminar: From 45 South – The Otago Myeloma Research Trust Presented by Dr Ian Morrison on 1 August, 5.30 at BNZ Partners Centre, Level 10, Ricoh House, 1 Victoria St RSVP by Friday 27 July to contact@multiplemyeloma.org.nz      
Continue Reading
1 10 11 12 13 14 16

Floor 7, 90 The Terrace
Wellington Central
New Zealand